DV
Dividend Vision

CVKD — Cadrenal Therapeutics, Inc. Common Stock

Cadrenal Therapeutics, Inc. Common Stock (CVKD)

Total return is -97.0% over the past 3.6 years, 202.1 points behind SPY at 105.1%. Its deepest 1-year drawdown was 87.0%.

Cadrenal Therapeutics is a late-stage biopharmaceutical company developing novel therapies for immune and thrombotic conditions, including Tecarfarin (an oral anticoagulant in Phase 3 trials), CAD-1005 (a first-in-class treatment for heparin-induced thrombocytopenia that completed Phase 2), and Frunexian (a factor XIa inhibitor in Phase 1). The company does not currently distribute dividends. This security appeals to investors seeking exposure to clinical-stage biopharmaceutical development with no current income component.

CVKD key facts

Asset type
Stock
Asset class
Equity
Inception date
01/20/2023
Last close
$1.87
Market cap
$6,692,959
Average volume
27905.0
Beta
1.752
Payout ratio
0.0
Forward P/E
0.0
EPS
$-5.59